(Q35763114)

10 August 2017

1 reference

title

Understanding treatments for bone loss and bone metastases in patients with prostate cancer: a practical review and guide for the clinician (English)

1 reference

10 August 2017

1 reference

1

Celestia S Higano

1 reference

10 August 2017

publication date

1 May 2004

1 reference

Urologic Clinics of North America

10 August 2017

published in

1 reference

10 August 2017

volume

31

1 reference

10 August 2017

issue

2

1 reference

10 August 2017

page(s)

331-352

1 reference

A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma

10 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2004.01.001

The potential role of bisphosphonates in prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2004.01.001

Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2004.01.001

Prostate cancer trends in the era of prostate-specific antigen. An update of incidence, mortality, and clinical factors from the SEER database

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2004.01.001

Background to and management of treatment-related bone loss in prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2004.01.001

Improved Survival in Patients with Locally Advanced Prostate Cancer Treated with Radiotherapy and Goserelin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2004.01.001

Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2004.01.001

Natural history of progression after PSA elevation following radical prostatectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2004.01.001

Side effects of androgen deprivation therapy: monitoring and minimizing toxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2004.01.001

Bone loss and the evolving role of bisphosphonate therapy in prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2004.01.001

Background for studies on the treatment of male osteoporosis: state of the art.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2004.01.001

Bisphosphonates to prevent osteoporosis in men receiving androgen deprivation therapy for prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2004.01.001

Management of treatment-related osteoporosis in men with prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2004.01.001

The use of biochemical markers of bone turnover in osteoporosis. Committee of Scientific Advisors of the International Osteoporosis Foundation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2004.01.001

Progressive osteoporosis during androgen deprivation therapy for prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2004.01.001

The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma: longitudinal evaluation and response to intermittent cyclic etidronate therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2004.01.001

The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade: a double blind, randomized, placebo-controlled crossover study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2004.01.001

Bone mineral density in patients with prostatic cancer treated with orchidectomy and with estrogens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2004.01.001

Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2004.01.001

Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2004.01.001

Low bone mineral density in hormone-naïve men with prostate carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2004.01.001

Androgen deprivation therapy for prostate cancer results in significant loss of bone density

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2004.01.001

Vitamin D supplementation and fracture incidence in elderly persons. A randomized, placebo-controlled clinical trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2004.01.001

Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2004.01.001

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2004.01.001

Mortality and institutionalization following hip fracture

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2004.01.001

Skeletal fracture associated with androgen suppression induced osteoporosis: the clinical incidence and risk factors for patients with prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2004.01.001

Bone fractures associated with luteinizing hormone-releasing hormone agonists used in the treatment of prostate carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2004.01.001

Incidence of bone fracture in patients receiving luteinizing hormone-releasing hormone agonists for prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2004.01.001

Fracture risk following bilateral orchiectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2004.01.001

American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2004.01.001

Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2004.01.001

Treatment of postmenopausal osteoporosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2004.01.001

Osteoporosis due to cancer treatment: pathogenesis and management

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2004.01.001

Bone density and fracture risk in men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2004.01.001

Diagnosis of osteoporosis and assessment of fracture risk

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2004.01.001

Clinical use of bone densitometry: scientific review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2004.01.001

Prediction of bone loss in postmenopausal women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2004.01.001

Markers of bone turnover for monitoring treatment of osteoporosis with antiresorptive drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2004.01.001

Complementary therapies for reducing the risk of osteoporosis in patients receiving luteinizing hormone-releasing hormone treatment/orchiectomy for prostate cancer: a review and assessment of the need for more research

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2004.01.001

Effect of calcium supplementation on bone loss in postmenopausal women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2004.01.001

Correcting calcium nutritional deficiency prevents spine fractures in elderly women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2004.01.001

Long-term effects of calcium supplementation on bone loss and fractures in postmenopausal women: a randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2004.01.001

Annual injection of vitamin D and fractures of aged bones

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2004.01.001

Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2004.01.001

Resistance exercise and bone turnover in elderly men and women.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2004.01.001

Resistance Exercise in Men Receiving Androgen Deprivation Therapy for Prostate Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2004.01.001

Alendronate treatment of established primary osteoporosis in men: results of a 2-year prospective study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2004.01.001

Alendronate for the Treatment of Osteoporosis in Men

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2004.01.001

Alendronate treatment of established primary osteoporosis in men: 3-year results of a prospective, comparative, two-arm study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2004.01.001

Tolerability of once-weekly alendronate in patients with osteoporosis: a randomized, double-blind, placebo-controlled study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2004.01.001

Effects of two intermittent alendronate regimens in the prevention or treatment of postmenopausal osteoporosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2004.01.001

Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2004.01.001

Metastatic bone disease: clinical features, pathophysiology and treatment strategies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2004.01.001

Treatment of painful prostatic bone metastases with oral etidronate disodium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2004.01.001

Pain relief and quality-of-life assessment following intravenous and oral clodronate in hormone-escaped metastatic prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2004.01.001

Ibandronate in the treatment of prostate cancer associated painful osseous metastases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2004.01.001

Effects of the bisphosphonate olpadronate in patients with carcinoma of the prostate metastatic to the skeleton

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2004.01.001

Biphosphonates as an adjunct to palliative therapy of bone metastases from prostatic carcinoma. A pilot study on clodronate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2004.01.001

Pathophysiology of bone metastases from prostate cancer and the role of bisphosphonates in treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2004.01.001

Effect of oral clodronate on bone pain. A controlled study in patients with metastic prostatic cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2004.01.001

Concomitant i.v. and oral clodronate in the relief of bone pain--a double-blind placebo-controlled study in patients with prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2004.01.001

A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2004.01.001

Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2004.01.001

Cox's Regression Model for Counting Processes: A Large Sample Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2004.01.001

Efficacy of bisphosphonates in the management of skeletal complications of bone metastases and selection of clinical endpoints

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2004.01.001

Nitrogen containing bisphosphonates induce apoptosis and inhibit the mevalonate pathway, impairing Ras membrane localization in prostate cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2004.01.001

Reduction in new metastases in breast cancer with adjuvant clodronate treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2004.01.001

Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2004.01.001

Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2004.01.001

Metastasis to bone: causes, consequences and therapeutic opportunities

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2004.01.001

Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2004.01.001

Suppression of prostate cancer induced bone remodeling by the endothelin receptor A antagonist atrasentan

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2004.01.001

Endothelin Inhibition: Novel Therapy for Prostate Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2004.01.001

Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2004.01.001

Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2004.01.001

Bisphosphonates for men with prostate cancer: sifting through the rubble

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2004.01.001

10.1016/J.UCL.2004.01.001

7 January 2021

Identifiers

DOI

1 reference

10 August 2017

1 reference